These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6653642)

  • 21. [Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension].
    Rostock G; Faulhaber HD; Gohlke HR; Prehm C
    Pharmazie; 1986 Apr; 41(4):258-60. PubMed ID: 3725870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naphthoxylactic acid after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Nov; 26(5):548-54. PubMed ID: 498695
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experiences with propranolol (Obsidan25) in hypertension therapy in pregnancy].
    Peiker G; Siegert C; Glöckner R; Völkner E; Traeger A
    Pharmazie; 1985 Sep; 40(9):645-7. PubMed ID: 4070348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Jun; 67(6):826-31. PubMed ID: 660467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.
    Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1993; 44(5):489-92. PubMed ID: 8359189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.
    Tomson T; Palm R; Källén K; Ben-Menachem E; Söderfeldt B; Danielsson B; Johansson R; Luef G; Ohman I
    Epilepsia; 2007 Jun; 48(6):1111-6. PubMed ID: 17381438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.
    Esler M; Zweifler A; Randall O; DeQuattro V
    Clin Pharmacol Ther; 1977 Sep; 22(3):299-308. PubMed ID: 330078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative account of propranolol metabolism in urine of normal man.
    Walle T; Walle UK; Olanoff LS
    Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. O-methylated catechol-like metabolites of propranolol in man.
    Walle T; Conradi EC; Walle UK; Gaffney TE
    Drug Metab Dispos; 1978; 6(4):481-7. PubMed ID: 28930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-hypertensive therapy with propranolol during pregnancy and lactation.
    Taylor EA; Turner P
    Postgrad Med J; 1981 Jul; 57(669):427-30. PubMed ID: 7312737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma concentrations of propranolol in patients with essential hypertension.
    Lehtonen A; Kanto J; Kleimola T
    Eur J Clin Pharmacol; 1977 Mar; 11(3):155-7. PubMed ID: 852494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of beta blockers (propranolol) in the treatment of arterial hypertension during pregnancy].
    Tcherdakoff P; Kreft C
    Acquis Med Recent; 1977; ():207-16. PubMed ID: 910599
    [No Abstract]   [Full Text] [Related]  

  • 36. Blood pressure, renin activity and heart rate changes during propranolol therapy of hypertension.
    Zweifler A; Esler M
    Am J Cardiol; 1977 Jul; 40(1):105-9. PubMed ID: 879001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin.
    Anthony L; Koshakji R; Wood AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):297-300. PubMed ID: 2776392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.